Eyestem - Trailblazing cell therapy company

How a 14-member biotech spent just $10M on a product global pharma wants to lap up

One of the three companies globally to show cell therapy results for dry AMD, an eye disorder affecting nearly 200 million globally, Bengaluru’s Eyestem is also eyeing a disruptive price.

Eyestem releases positive results from phase 1 trial in patients with geographic atrophy

Eyecyte-RPE trial involved 9 patients with geographic atrophy, using three ascending dose levels of hiPSC-derived RPE cells. No serious adverse events were reported, and patients showed an average vision improvement of 14.9 letters on ETDRS tests.

Eyestem to begin human trials for its pioneering Dry AMD treatment

Dry AMD, a leading cause of vision loss in the ageing population of people over 50, has long been a challenge due to the limited availability of effective treatments and the high costs associated with emerging therapeutic options.

Eyestem’s promising pipeline of products catches the eye of traditional pharma companies

Two pharmaceutical companies and a vaccine-maker invested in Eyestem (2022), putting the spotlight on the cell therapy company’s product pipeline. The six-year old company’s potential therapy for dry age-related macular degeneration, a global unmet medical need, awaits regulatory approvals in India for trial in humans, even as the company prepares to take the investigational new drug to Australia, says Eyestem co-founder and Chief Executive Jogin Desai.

Eyestem: A vision for the future

Medical entrepreneurs at the Bengaluru-based Eyestem are developing what they hope will be a platform that will bring cell therapy to the masses.

Affordable gene and cell therapies need of the hour: Dr Kapil Bharti, Scientific Director, National Eye Institute

Eyestem Research, a pioneering cell therapy company, with a vision to democratize cutting-edge technologies for the bottom 99%, hosted India's first retinal cell and gene therapy conference.

Eyestem files for IND approval for its product to treat geographic atrophy

Eyestem Research has announced the submission of IND application to CDSCO to start first in-human trials of Eyecyte-RPE™for subjects.

Eyestem bags the Top Innovator award : ET Startup Awards 2022

It’s estimated that cell therapy products will cost more than $450,000 per injection globally. The Bengaluru-based Eyestem’s mission to democratise access to such treatment by bringing the cost down to less than a 50th of that won it the Top Innovator Award at the ET Startup Awards 2022.

Eyestem raises Series A round from Biological E, Alkem and others

Eyestem, a Bengaluru-based cell therapy company, has raised $6.4 million (Rs 51 Crore) in a Series A round led by three pharma majors - Biological E. Limited (BE), Alkem, NATCO and Anurag and Karan Bagaria, promoters of Kemwell Biopharma. Existing investors Endiya Partners and Kotak Private Equity also participated in this round

Eyestem has a visionary approach to make cell therapy affordable in India

Eyestem's premier cell therapy solution to treat age-related macular degeneration or AMD, the leading cause for incurable blindness should be available in the market by 2024, heralding a new era of home-grown sophisticated frontier Lifesciences led solutions.

Eyestem is breaking cell therapy price barrier and its first target is an incurable eye disease

Bengaluru based Eyestem has set its sight on finding an affordable cure for an incurable eye disease – dry age-related macular degeneration (AMD) – the first of many conditions it wants to treat using a unique cell therapy platform.

Eyestem raises funds from Endiya Partners

This investment will enable Eyestem to reach their goal of becoming one of the first few companies in the world to develop a treatment for Dry Age-related Macular Degeneration (Dry AMD), the leading cause of incurable blindness affecting almost 170 million people – mostly above 50 years of age – across the globe.